Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's Q3 2024 revenue is expected to exceed projections as concerns rise over compounded GLP-1 medications.
Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand.
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Stocks were lower Thursday as traders weighed a greater-than-expected increase in weekly jobless claims and awaited the U.S.
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
Hims & Hers is making GLP-1 weight loss medications more accessible with a 50% discount for front-line heroes. Mihir Gandhi ...
On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $17.77 which represents a slight increase of $0.06 or 0.34% from the prior close of $17.71. The stock opened at ...
Hims & Hers stock is currently in the middle of a deep drawdown. Read why I maintain my strong buy rating on HIMS stock.
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback